Partnering, Collaboration & Pipeline


With a long scientific tradition and strong background in the discovery and development of antibodies, this is where YUMAB focuses its primary work. For additional services, we have built an excellent and growing network of potent partners from academia, clinics and industry allowing to access a broader expertise and technology portfolio (e.g. peptide synthesis or cell line generation). These external services are managed, supervised and controlled by YUMAB. This allows our clients to access many different technologies by just contracting and communicating with us.


Besides contract research, YUMAB offers partnered antibody research & development for the mutual benefit of all partners. Focal points are novel technologies or novel indications and immunotherapeutic strategies. Our concept is to bring the best technologies and ideas together and to push the boundaries of current drug development to a new level.


YUMAB’s internal antibody discovery and development pipeline mostly contains projects from our collaborations. Internal projects are mainly started to develop novel antibody technologies (proof of concept studies). Our novel antibody drug candidates are available for out-licensing or partnering.
Our pipeline projects do not interfere with our core business – contract research and R&D services.


Science Campus Braunschweig-Süd
Inhoffenstr. 7
38124 Braunschweig – Germany

Phone: +49 531 481170-0